Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at JPMorgan Chase & Co.

Maze Therapeutics (NASDAQ:MAZE) had its price objective increased by investment analysts at JPMorgan Chase & Co. from $52.00 to $58.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 92.52% from the company’s previous close.

A number of other research firms also recently issued reports on MAZE. HC Wainwright upped their target price on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target for the company. Truist Financial began coverage on shares of Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 price target for the company. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and a consensus target price of $66.44.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE traded up $1.12 during midday trading on Tuesday, hitting $30.13. The stock had a trading volume of 384,537 shares, compared to its average volume of 682,203. The firm has a market cap of $1.50 billion, a P/E ratio of -9.31 and a beta of 4.46. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $53.65. The company’s 50-day simple moving average is $45.37 and its 200 day simple moving average is $37.95.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Insiders Place Their Bets

In other news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares in the company, valued at approximately $464,967.81. The trade was a 41.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Harold Bernstein sold 30,000 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 112,500 shares of company stock worth $5,132,812.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its position in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. raised its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics during the 4th quarter worth $43,000. Finally, Russell Investments Group Ltd. lifted its holdings in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.